Trial Profile
Clinical and serological response to Obinutuzumab in the treatment of Rituximab- Unresponsive IgM Anti-Myelin-Associated-Glycoprotein (MAG)-Mediated-Neuropathy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2018
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Peripheral neuropathies
- Focus Pharmacodynamics; Therapeutic Use
- 11 May 2018 New trial record
- 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology